Chi­na's Yisheng­Bio chron­i­cles come­back sto­ry in Hong Kong IPO while plot­ting big moves in in­fec­tious dis­eases, can­cer

It can be tough to be a vac­cine de­vel­op­er in Chi­na.

Yisheng­Bio shed some light on the reg­u­la­to­ry hoops and hur­dles it had to jump through since launch­ing its first ra­bies vac­cine in 2003 — and the grand plans it has for the glob­al pipeline in in­fec­tious dis­eases and can­cer — in an IPO fil­ing on the HKEX.

The 2014 dis­pute that founder and chair­man Zhang Yi got in­to with the Chi­nese FDA, for in­stance, turned out to have cost a lot more than just a few vac­cine batch­es that didn’t get re­leased. While the com­pa­ny said it had vol­un­tar­i­ly halt­ed man­u­fac­tur­ing ac­tiv­i­ties, re­port­ed the con­t­a­m­i­na­tion and be­gan a re­view of the fa­cil­i­ties, the reg­u­la­tors per­formed an in­spec­tion and sus­pend­ed the GMP li­cense for a cou­ple of months while al­so block­ing re­lease of 117 oth­er lots of the YS­JA ra­bies vac­cine. At­tempts to take the then-CF­DA to court end­ed in vain.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.